Prevalence of relevant multi-drug resistant (MDR) pathogens in a bronchiectasis (BE) cohort. Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019
Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003
Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004
Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Drug resistance patterns in patients with multi-drug resistant tuberculosis (MDR – TB) Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012
Is health care-associated pneumonia itself a predisposing factor for multi-drug resistant organisms? Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019
Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Outcome of multidrug resistant tuberculosis (MDR-TB) treatment with possible influencing factors Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004
Short course of chemotherapy of multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005
Surgical treatment of destructive pulmonary tuberculosis (TB) with multi-drug resistance (MDR) Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Artificial pneumothorax in the treatment of multi drug resistant tuberculosis (MDR TB) Source: Eur Respir J 2006; 28: Suppl. 50, 586s Year: 2006
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003
Increasing incidence of fluoroquinolone resistant tuberculosis in Bombay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005
Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review Source: Eur Respir J 2008; 31: 625-632 Year: 2008
Primary multi-drug resistant tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004